



HAL
open science

Onset of MELAS due to the m.3243A > G mutation is early if the large phenotypic variability is considered

Josef Finsterer, Sinda Zarrouk-Mahjoub

► To cite this version:

Josef Finsterer, Sinda Zarrouk-Mahjoub. Onset of MELAS due to the m.3243A > G mutation is early if the large phenotypic variability is considered. *Molecular Genetics and Metabolism Reports*, 2017, 10, pp.23. 10.1016/j.ymgmr.2016.12.001 . pasteur-02056121

HAL Id: pasteur-02056121

<https://riip.hal.science/pasteur-02056121>

Submitted on 4 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



Correspondence

Onset of MELAS due to the m.3243A>G mutation is early if the large phenotypic variability is considered☆☆☆


Keywords:

mtDNA
m.3243A>G
MELAS
Gene
Mitochondrial disorder
Stroke-like episode

Letter to the Editor

With interest we read the article by Sunde et al. about a female with MELAS syndrome with onset at age 49 years and four stroke-like episodes (SLEs) during the first 2 years who was followed-up for 5 years [1]. We have the following comments and concerns.

The morphological equivalent of a SLE is a stroke-like lesion on cerebral MRI during the acute stage. Only one MRI during the asymptomatic stage is described showing left occipital cystic encephalomalacia and white matter lesions [1]. No MRI figure is presented. The patient is reported to have had experienced four SLEs during the first 2 years after diagnosis [1]. Were ever typical abnormalities (DWI and ADC hyperintensity beyond a vascular territory) detected in the acute stage during any of these SLEs? Did these lesions change in a typical manner over time [2]? How did the authors exclude that the occipital lesion resulted from an ischemic stroke?

We do not agree with the notion that MELAS was of late onset [1]. The patient is of short stature since childhood, hypothyroidism was detected at age 30 years, and hypoacusis started in her mid-30s [1]. Additionally, the patient had migraine, most likely since adolescence, and nausea. These are all typical manifestations of the m.3243A>G

mutation, why physicians could have suspected a mitochondrial disorder (MID) much earlier [3]. When did nausea and migraine start?

A mainstay of treating MIDs is the avoidance of mitochondrion-toxic drugs [4]. Why did the patient receive phenytoin, of which it is well-known that it has mitochondrion-toxic properties and should be avoided in MIDs [4]. Why does she require four antiepileptic drugs (AEDs)? Was ever a monotherapy with increased lamotrigine tried? The patient complains about generalised fatigue during follow-up [1]. Is levetiracetam or clonazepam the culprit?

Overall, SLEs require MRI documentation, the patient might profit from modification of her AED-therapy, and all phenotypic manifestations should be considered when diagnosing MELAS.

References

- [1] K. Sunde, P.R. Blackburn, A. Cheema, J. Gass, J. Jackson, S. Macklin, P.S. Atwal, Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS), *Mol. Genet. Metab. Rep.* 9 (2016) 94–97.
- [2] J. Finsterer, Management of mitochondrial stroke-like-episodes, *Eur. J. Neurol.* 16 (2009) 1178–1184.
- [3] A.W. El-Hattab, A.M. Adesina, J. Jones, F. Scaglia, MELAS syndrome: clinical manifestations, pathogenesis, and treatment options, *Mol. Genet. Metab.* 116 (2015) 4–12.
- [4] J. Finsterer, Toxicity of antiepileptic drugs to mitochondria, *Handb. Exp. Pharmacol.* (2016) (in press).

Josef Finsterer, MD, PhD¹

Krankenanstalt Rudolfstiftung, Vienna, Austria

Corresponding author at: Postfach 20, 1180 Vienna, Austria.

E-mail address: fipaps@yahoo.de.

Sinda Zarrouk-Mahjoub, PhD¹

University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia

1 December 2016

☆ There are no conflicts of interest.

☆☆ No funding was received.

¹ Both authors contributed equally.